Introduction
The external glycoprotein of human immunodeficiency virus type 1 (HIV-1), gp 120, and the transmembrane region, gp41, contain several domains which have been associated with neutralization of HIV-1 in vitro, The principal neutralizing domain (PND) is in the third variable loop of gpl20 and is expressed on the virion surface (LaRosa et al., 1990) . Two such domains have also been identified on gp41, the 'Kennedy' epitope in the transmembrane region at residues 735 to 752 (Kennedy et at., 1986) and more recently in a conserved region at residues 647 to 671 (Broliden et al., 1992) . Although gp41 exists in trimeric or tetrameric form within the virion membrane (Pinter et al., 1989) , cleavage of covalent bonds between gpl20 and gp41 in the mature virion leads to the shedding of gpl20 thereby exposing gp41 at least in T cell-tropic laboratory strains of HIV-1 (Kieny et al., 1986; Schneider et al., 1986; Gelderblom et al., 1989) . The PND is involved in strain-specific neutralization, but the gp41 epitope may be important in broader cross-neutralization and is more conserved ~Present address: Division of Virology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 IAA, U.K. among HIV-1 strains. A high percentage of sera from HIV-l-infected individuals bind peptides corresponding to the PND in ELISA but few bind peptides showing identity to the Kennedy epitope (Davis et al., 1990; Broliden et al., 1992, J. Weber, personal communication; C. Vella, unpublished data) . This may suggest that the epitope is conformation-dependent, or of poor immunogenicity. Evans et al. (1989) reported the construction of a poliovirus/HIV-1 chimeric virus, S 1/env/3, expressing a gp41 epitope (residues 735 to 752) from HIV IIIB in antigenic site 1 at the pentameric apex of the virus capsid (VP1). S1/env/3 showed dual antigenicity in small animals, eliciting antibodies that recognized both poliovirus type 1 and HIV-1. Four murine monoclonal antibodies (MAbs) raised against this chimera were able to neutralize HIV-1 in vitro. These results suggested that the HIV sequence presented on the surface of the poliovirus particle conformationally resembles the epitope in its native context of gp41. This being the case, it is likely that residues within the epitope critical for the neutralization of the chimera may also be important for the neutralization of HIV-1. To dissect this region of gp41 further, an extensive panel of MAb neutralizationresistant variants of S1/env/3 were generated and characterized.
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Resistant to neutralization at a 1 : 10 dilution of MAb.
Methods
MAbs. A panel of 10 S1/env/3 site 1-specific (HIV insert-specific) MAbs and eight Sabin 1-specific MAbs were prepared as described by Evans et aL (1989) .
HIV-1. HIV strains RF, MN and IIIB were kindly provided by the MRC AIDS Reagent Project (AIDS Directed Programme reagents 101, 102 and 103, respectively). Virus pools were prepared from persistently infected H9 cultures (HIV-1 RF) (Popovic et al., 1984) or by direct infection of H9 (HIV-1 MN) or C8166 (HIV-1 IIIB) (Hahn et al., 1983 ) cells using standard techniques. The TCID~0 of the virus pools was determined by syncytium assay in C8166 cells.
MAb neutralization escape mutants were selected from 10 doubly plaque-purified parental stocks of S 1/env/3 using six S1/env/3 MAbs (1575, 1576, 1577, 1578, 1579 and 1583) according to the method of Minor et al. (1983) .
Characterization of neutralization escape mutants. The neutralization pattern of mutants was determined against the 10 Sl/env/3 MAbs and eight Sabin 1 MAbs. The microneutralization assay used was as described by Vella et al. (1991) using serial twofold dilutions of MAb (1 : 10 to 1 : 160) against a constant virus challenge (100 TCIDs0).
HIV neutralization assay. The complete panel of MAbs including two specific for the Sabin type 1 strain of poliovirus was examined for anti-HIV-1 activity in a microneutralization assay (syncytium inhibition) (according to the method of T. Corcoran, collaborating investigator, Lab L, in D 'Souza et al., 1991) . Neutralization end-point titres were expressed as the reciprocal of the highest dilution of antibody at which 90 to 100% syncytia were neutralized. Controls included a sheep anti-gp 120 neutralizing polyclonal serum ($216 kindly donated by M. Page (Page et al., 1991) , sera from HIV-l-seropositive and -seronegative individuals and a virus back-titration.
Sequence analysis of escape mutants. Poliovirus/HIV chimera RNA was extracted from tissue culture fluid according to the method of Macadam et al. (1989) and cDNA transcripts were prepared using an oligonucleotide complementary to nucleotide positions 3006 to 3030 followed by amplification by PCR using the same primer and an oligonucleotide of the same sense as the virion RNAs corresponding to nucleotide positions 2530 to 2556. The dsDNA PCR product was purified using the Prep-A-Gene kit (Bio-Rad) and sequenced by the dideoxynucleotide method (Sanger et al., 1977) .
Pepscan analysis. The binding pattern of four MAbs (1575 MAbs ( , 1577 MAbs ( , 1578 MAbs ( and 1573 was examined by Pepscan analysis. Overlapping peptides of multiple length (three to nine amino acids) spanning the HIV IIIB epitope in S1/env/3 were synthesized on solid supports and tested as described by Geysen et al. (1984) .
Results
Neutralization escape mutants S1/env/3 expresses the HIV IIIB gp41 sequence DRPEGIEEEGGERDRDRS (residues 735 to 752) in antigenic site 1. All 10 MAbs produced neutralized S1/env/3 at reciprocal dilutions of ~> 2560 in poliovirus neutralization assays and failed to neutralize the parent Sabin 1 virus. Thus all were specific for the inserted HIV sequence.
The 240 S1/env/3 MAb neutralization-resistant mutants isolated could be divided into three distinct groups of viruses designed A, B and C on the basis of their neutralization pattern (Table 1) . One-hundred and fifty isolates were resistant to MAbs 1575, 1578 and 1579, but remained sensitive to neutralization by the remaining seven, whereas 80 isolates were sensitive to MAbs 1575, 1578 and 1579, but resistant to the remaining seven. Ten isolates were sensitive to MAbs 1575, 1578, 1579 and 1583 but resistant to the remaining six. On this basis MAbs 1575, 1578 and 1579 were designated group 1 and the remainder group 2. All escape mutants remained sensitive to neutralization by MAbs against sites 2a, 2b, 3 and 4 of Sabin 1 (Minor et al., 1986 (Minor et al., , 1987 ; data not shown).
Representative mutants from each group were sequenced through the HIV insert and the results are summarized in Table 2 . Of nine mutants resistant to group 1 MAbs, six had single amino acid changes in the insert at residues corresponding to 740, 742 or 743 of gp41. No change was found for three of the mutants, suggesting that changes outside the region sequenced affected the binding at residues 740 to 743 by these MAbs. * Determined by syncytium inhibition assay in which serial twofold dilutions of antibody were challenged with 100 TCIDs0 of HIV-1. The end-point was taken as the dilution in which 50 % of wells showed 90 % (10 syncytia or fewer) inhibition of c.p.e. Results for HIV IIIB are the mean of at least three independent assays.
Nine of the 10 sequenced mutants resistant to all the group 2 MAbs had single amino acid changes occurring between residues 747 and 750. The tenth mutant contained a deletion of three amino acids, RDR (residues 747, 748 and 749), plus a substitution at 752 (S--, R). Two mutants resistant to all group 2 MAbs other than MAb 1583 contained a substitution (G ~ S) at residue 745, between the two binding sites identified by group 1 and 2 MAbs.
Pepscan analysis
The minimum essential binding epitope was determined for four MAbs. Group 1 MAbs 1575 (Fig. la) and 1578 ( Fig. 1 b) recognized residues 740 to 743 (IEEE). Group 2 MAbs 1577 (Fig. lc) and 1583 (Fig. ld) bound to residues 746 to 750 (ERDRD). These results are consistent with the neutralization escape mutant data and support the view that in antigenic site 1 of Sabin 1, the HIV sequence contains two discrete epitopes
7~5D RPEGIEEEGGERDRDRS
TM .
Neutralization of HIV-1
The MAb panel was tested for neutralization activity against three isolates of HIV-I: IIIB, in which the Kennedy sequence is identical with the S1/env/3 insert, RF which differs from S1/env/3 and IIIB at residue 742 (E--* G) and MN which differs at residue 751 (R ~ T). Eight of the 10 neutralized HIV-1 IIIB as shown in Table  2 suggesting that the presentation of this sequence is comparable in the poliovirus/HIV-1 chimera and in this strain. 
* Boxed sequences are the regions identified as epitopes recognized by MAbs raised against S1/env/3.
Some neutralization of isolate RF was seen with two of the group 2 MAbs (Table 2 ), but group 1 MAbs, which were affected by an identical amino acid substitution in the chimera, were unable to neutralize the RF isolate. Neutralization of isolate MN was not detected although its sequence was identical to that of the IIIB isolate for the sequence inserted into S1/env/3 except in the C-terminal region at the residue corresponding to amino acid 751.
Discussion
Engineered poliovirus particles have been used to present defined amino acid sequences in place of a well characterized neutralization epitope on VP1 (Rose & Evans, 1991) . A proportion of such chimeras, when administered to small animals induce the production of antibodies that recognize not only the immunogen, but also the protein from which the immunogen was derived (Rose & Evans, 1991; Burke et al., 1988; Vella et al., 1991) . In specific cases including foot-and-mouth disease virus (Kitson et al., 1991) , HIV (Rose & Evans, 1991) , poliovirus type 3 (Burke et al., 1988) and rhinovirus (Altmeyer et al., 1991) MAbs raised against the chimera also neutralize the foreign virus. This suggests that the presentation of the epitope on the surface of the poliovirus particle resembles that of the native protein.
We have therefore further investigated the specific recognition of residues 735 to 752 of HIV-1 IIIB when presented on a poliovirus particle (S1/env/3), and in the native context of gp41, by a panel of murine MAbs raised against the chimeric poliovirus. The antibodies recognized two principal epitopes in the chimeric poliovirus and neutralization of the RF but not the MN strain by the MAbs was consistent with the view that the epitope was presented in a similar manner in the chimera and on HIV.
The epitopes identified by S1/env/3 MAbs at residues 740 to 743 and 746 to 750 may also be targets for the neutralization of HIV-1 in vivo based on the variation in the sequence identified. When the 18 amino acid sequence of this region from 66 HIV-1 isolates from divergent geographical locations was examined (Los Alamos database, last updated June 1992) the sequences of 28 strains were identical with HIV IIIB and S1/env/3, and the sequence of most of the 38 variant strains contained only one or two substitutions. However, in 27 of the strains that had substitutions these substitutions occurred at either or both of the neutralization epitopes identified in S1/env/3. The data are summarized in Table 3 . This may suggest that such changes are due to immune selection. The failure of the MN strain to be neutralized by any MAb may be due to the difference in the C-terminal region of the sequence which can affect the conformation of the whole region.
The results reported here with group 1 MAbs 1575 and 1578, and group 2 MAb 1583 differ from those of Evans et al. (1989) . In that study MAb 1575 was found to neutralize at a low titre strain RF whereas MAb 1578 did not neutralize any of the HIV-1 strains tested. Furthermore, MAb 1583 neutralized strain RF. It is possible that the differences observed with MAbs 1578 and 1583 were due to variation in the batches of MAb used. In support of this, when testing different MAb batches we did find total loss of neutralizing activity against strain IIIB with one of several batches of MAb 1578, and a significant reduction in IIIB strain titre (10-fold) with one batch of MAb 1577. However, we cannot explain the observed differences with MAb 1575 which selects a substitution at residue 742 in neutralization mutants which is identical to the substitution present in the RF strain.
It is difficult to envisage a mechanism by which an antibody to an epitope in a transmembrane region can bring about neutralization. We have considered postinfection neutralization, but find complete loss of neutralizing activity against strain IIIB when the S1/env/3 MAbs are added 1 h after the infection of cells (C. Vella, unpublished data). Recently, Broliden et al. (1992) showed that seroreactivity with peptides corresponding to the two gp41 neutralizing epitopes at residues 647 to 671 and 735 to 752 correlated with high HIV-1 neutralizing antibody titres. Moreover, neutralization was more broadly reactive than that seen with antibody directed against V3. Much of the recent research has concentrated on the PND on gpl20, but this epitope shows hypervariability both within HIV-infected individuals and between virus strains. On the other hand, our results together with those of Broliden et aI. (1992) with a more conserved epitope do suggest that it may be significant in the neutralization of HIV-1 in vivo, and deserves further consideration.
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